Published in J Neurosci on July 20, 2011
Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci (2012) 2.92
Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med (2012) 2.77
Soluble Aβ oligomer production and toxicity. J Neurochem (2011) 1.83
Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Front Genet (2014) 1.56
The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease. J Neurosci (2012) 1.50
Prion protein at the crossroads of physiology and disease. Trends Neurosci (2011) 1.26
Prion propagation, toxicity and degradation. Nat Neurosci (2012) 1.25
An N-terminal fragment of the prion protein binds to amyloid-β oligomers and inhibits their neurotoxicity in vivo. J Biol Chem (2013) 1.18
The dendritic hypothesis for Alzheimer's disease pathophysiology. Brain Res Bull (2013) 1.14
SIRPα polymorphisms, but not the prion protein, control phagocytosis of apoptotic cells. J Exp Med (2013) 1.11
FcγRIIb mediates amyloid-β neurotoxicity and memory impairment in Alzheimer's disease. J Clin Invest (2013) 1.08
α-Secretase-derived fragment of cellular prion, N1, protects against monomeric and oligomeric amyloid β (Aβ)-associated cell death. J Biol Chem (2011) 1.07
Fyn kinase inhibition as a novel therapy for Alzheimer's disease. Alzheimers Res Ther (2014) 1.03
Amyloid-β nanotubes are associated with prion protein-dependent synaptotoxicity. Nat Commun (2013) 1.00
Comprehensive behavioral characterization of an APP/PS-1 double knock-in mouse model of Alzheimer's disease. Alzheimers Res Ther (2013) 0.97
Amyloid-β induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease. Prion (2012) 0.97
Alzheimer's disease Aβ assemblies mediating rapid disruption of synaptic plasticity and memory. Mol Brain (2012) 0.90
Prion-Protein-interacting Amyloid-β Oligomers of High Molecular Weight Are Tightly Correlated with Memory Impairment in Multiple Alzheimer Mouse Models. J Biol Chem (2015) 0.88
Cellular prion protein and NMDA receptor modulation: protecting against excitotoxicity. Front Cell Dev Biol (2014) 0.87
The cellular prion protein traps Alzheimer's Aβ in an oligomeric form and disassembles amyloid fibers. FASEB J (2013) 0.86
Protease resistant protein cellular isoform (PrP(c)) as a biomarker: clues into the pathogenesis of HAND. J Neuroimmune Pharmacol (2013) 0.85
Natural amyloid-β oligomers acutely impair the formation of a contextual fear memory in mice. PLoS One (2012) 0.85
Breaking the Code of Amyloid-β Oligomers. Int J Cell Biol (2013) 0.84
The P's and Q's of cellular PrP-Aβ interactions. Prion (2012) 0.83
Amyloid beta precursor protein and prion protein have a conserved interaction affecting cell adhesion and CNS development. PLoS One (2012) 0.82
Intracellular oligomeric amyloid-beta rapidly regulates GluA1 subunit of AMPA receptor in the hippocampus. Sci Rep (2015) 0.81
Binding affinity of amyloid oligomers to cellular membranes is a generic indicator of cellular dysfunction in protein misfolding diseases. Sci Rep (2016) 0.80
Glutamate receptors function as scaffolds for the regulation of β-amyloid and cellular prion protein signaling complexes. Mol Brain (2015) 0.80
Overcoming barriers and thresholds - signaling of oligomeric Aβ through the prion protein to Fyn. Mol Neurodegener (2013) 0.80
Regulation of amyloid-β production by the prion protein. Prion (2012) 0.79
A coimmunization vaccine of Aβ42 ameliorates cognitive deficits without brain inflammation in an Alzheimer's disease model. Alzheimers Res Ther (2014) 0.78
Increasing the Receptor Tyrosine Kinase EphB2 Prevents Amyloid-β-induced Depletion of Cell Surface Glutamate Receptors by a Mechanism That Requires the PDZ-binding Motif of EphB2 and Neuronal Activity. J Biol Chem (2015) 0.78
The neurodegeneration in Alzheimer disease and the prion protein. Prion (2013) 0.78
Regulation of Synaptic Amyloid-β Generation through BACE1 Retrograde Transport in a Mouse Model of Alzheimer's Disease. J Neurosci (2017) 0.77
Alzheimer's amyloid-β oligomers rescue cellular prion protein induced tau reduction via the Fyn pathway. ACS Chem Neurosci (2013) 0.77
The biological function of the cellular prion protein: an update. BMC Biol (2017) 0.76
Involvement of 'stress-response' kinase pathways in Alzheimer's disease progression. Curr Opin Neurobiol (2014) 0.76
Single-molecule imaging reveals that small amyloid-β1-42 oligomers interact with the cellular prion protein (PrP(C)). Chembiochem (2014) 0.76
The Biological Function of the Prion Protein: A Cell Surface Scaffold of Signaling Modules. Front Mol Neurosci (2017) 0.75
Characterization of AD-like phenotype in aged APPSwe/PS1dE9 mice. Age (Dordr) (2016) 0.75
FcγRIIb-SHIP2 axis links Aβ to tau pathology by disrupting phosphoinositide metabolism in Alzheimer's disease model. Elife (2016) 0.75
Soluble prion protein and its N-terminal fragment prevent impairment of synaptic plasticity by Aβ oligomers: Implications for novel therapeutic strategy in Alzheimer's disease. Neurobiol Dis (2016) 0.75
Ablation of Prion Protein in Wild Type Human Amyloid Precursor Protein (APP) Transgenic Mice Does Not Alter The Proteolysis of APP, Levels of Amyloid-β or Pathologic Phenotype. PLoS One (2016) 0.75
Cellular prion protein targets amyloid-β fibril ends via its C-terminal domain to prevent elongation. J Biol Chem (2017) 0.75
Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med (2008) 17.09
High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci (2000) 9.85
Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science (2007) 8.56
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature (2009) 6.99
Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron (2007) 6.60
Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci (2010) 5.03
Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A (1997) 4.92
2011 Alzheimer's disease facts and figures. Alzheimers Dement (2011) 3.91
Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J Neurosci (2010) 3.36
Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature (2010) 3.36
The prion's elusive reason for being. Annu Rev Neurosci (2008) 3.23
Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem (2007) 3.13
Probing the biology of Alzheimer's disease in mice. Neuron (2010) 2.96
Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci (2011) 2.96
Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci U S A (2010) 2.86
Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron (2010) 2.34
Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci (2005) 2.34
Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci (2009) 2.33
Prion protein and Abeta-related synaptic toxicity impairment. EMBO Mol Med (2010) 2.25
The prion protein as a receptor for amyloid-beta. Nature (2010) 2.10
Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci (2008) 2.09
Levels and alternative splicing of amyloid beta protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer's disease. J Biol Chem (1995) 1.95
Amyloid oligomers: formation and toxicity of Abeta oligomers. FEBS J (2010) 1.78
Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease. Genes Brain Behav (2005) 1.58
Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. J Neurosci (2009) 1.54
Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein. J Neurosci (2010) 1.44
Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J Neurosci (2004) 1.43
Increased sensitivity to seizures in mice lacking cellular prion protein. Epilepsia (1999) 1.39
Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci (2008) 1.33
Enhanced susceptibility of Prnp-deficient mice to kainate-induced seizures, neuronal apoptosis, and death: Role of AMPA/kainate receptors. J Neurosci Res (2007) 1.33
beta -Amyloid peptide activates alpha 7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Biol Chem (2002) 1.32
MAPK, beta-amyloid and synaptic dysfunction: the role of RAGE. Expert Rev Neurother (2009) 0.99
Threshold for epileptiform activity is elevated in prion knockout mice. Neuroscience (2011) 0.88
Cellular prion protein: implications in seizures and epilepsy. Cell Mol Neurobiol (2002) 0.83
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21
Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science (2007) 8.56
Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron (2007) 6.60
Alzheimer mechanisms and therapeutic strategies. Cell (2012) 5.24
Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci (2010) 5.03
Inflammation in neurodegenerative disease--a double-edged sword. Neuron (2002) 4.95
SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem (2005) 3.38
Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature (2010) 3.36
A network dysfunction perspective on neurodegenerative diseases. Nature (2006) 3.33
100 years and counting: prospects for defeating Alzheimer's disease. Science (2006) 3.24
Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell (2012) 3.16
Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem (2007) 3.13
Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol (2009) 3.12
Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci (2011) 2.96
The many faces of tau. Neuron (2011) 2.89
Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron (2006) 2.88
Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci U S A (2012) 2.84
Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc Natl Acad Sci U S A (2003) 2.83
Tau reduction prevents Abeta-induced defects in axonal transport. Science (2010) 2.57
Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci (2005) 2.34
Computed tomographic colonography to screen for colorectal cancer, extracolonic cancer, and aortic aneurysm: model simulation with cost-effectiveness analysis. Arch Intern Med (2008) 2.24
Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci U S A (2003) 2.24
Biomechanical comparison of anterior and posterior stabilization methods in atlantoaxial instability. J Neurosurg (2004) 2.21
Transsynaptic progression of amyloid-β-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron (2010) 2.10
Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci (2008) 2.09
RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J (2004) 2.08
Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J Neurosci (2004) 2.07
Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology. J Clin Invest (2006) 1.87
Vulnerability of dentate granule cells to disruption of arc expression in human amyloid precursor protein transgenic mice. J Neurosci (2005) 1.79
Neuroscience: Alzheimer's disease. Nature (2009) 1.79
Physiologic brain activity causes DNA double-strand breaks in neurons, with exacerbation by amyloid-β. Nat Neurosci (2013) 1.72
Reduction in mitochondrial superoxide dismutase modulates Alzheimer's disease-like pathology and accelerates the onset of behavioral changes in human amyloid precursor protein transgenic mice. J Neurosci (2006) 1.69
Imbalance between GABAergic and Glutamatergic Transmission Impairs Adult Neurogenesis in an Animal Model of Alzheimer's Disease. Cell Stem Cell (2009) 1.68
Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol (2013) 1.68
Anterior cervical fusion using dense cancellous allografts and dynamic plating. Neurosurgery (2004) 1.61
Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. J Neurosci (2002) 1.56
Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. J Neurosci (2009) 1.54
Reelin depletion in the entorhinal cortex of human amyloid precursor protein transgenic mice and humans with Alzheimer's disease. J Neurosci (2007) 1.53
Genes contributing to prion pathogenesis. J Gen Virol (2008) 1.51
Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11,12-epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BK(Ca) channels. Circulation (2003) 1.46
Apolipoprotein E: diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer's disease. J Mol Neurosci (2004) 1.45
Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein. J Neurosci (2010) 1.44
Endoscopic harvesting of the sural nerve graft: technical note. Neurosurgery (2006) 1.44
Androgens protect against apolipoprotein E4-induced cognitive deficits. J Neurosci (2002) 1.44
Cross-species translation of the Morris maze for Alzheimer's disease. J Clin Invest (2016) 1.43
Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J Neurosci (2004) 1.43
Paths of convergence: sirtuins in aging and neurodegeneration. Neuron (2008) 1.43
High beta-secretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid-beta levels: implications for the treatment of Alzheimer disease. J Biol Chem (2005) 1.40
Changes in adjacent-level disc pressure and facet joint force after cervical arthroplasty compared with cervical discectomy and fusion. J Neurosurg Spine (2007) 1.36
Instrumentation in patients with spinal infection. Neurosurg Focus (2004) 1.36
Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci (2008) 1.33
Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation. Nat Med (2004) 1.24
Synaptic depression and aberrant excitatory network activity in Alzheimer's disease: two faces of the same coin? Neuromolecular Med (2009) 1.21
Human P301L-mutant tau expression in mouse entorhinal-hippocampal network causes tau aggregation and presynaptic pathology but no cognitive deficits. PLoS One (2012) 1.19
Collagen VI protects neurons against Abeta toxicity. Nat Neurosci (2009) 1.19
Range of motion change after cervical arthroplasty with ProDisc-C and prestige artificial discs compared with anterior cervical discectomy and fusion. J Neurosurg Spine (2007) 1.19
Iatrogenic sciatic nerve injuries at buttock and thigh levels: the Louisiana State University experience review. Neurosurgery (2009) 1.16
Nitinol spring rod dynamic stabilization system and Nitinol memory loops in surgical treatment for lumbar disc disorders: short-term follow up. Neurosurg Focus (2007) 1.13
Tau reduction does not prevent motor deficits in two mouse models of Parkinson's disease. PLoS One (2011) 1.10
History of minimally invasive spine surgery. Neurosurgery (2002) 1.08
Phospholipase A2 and arachidonic acid in Alzheimer's disease. Biochim Biophys Acta (2010) 1.07
A Pilot Study of Mood Ratings Captured by Mobile Phone Versus Paper-and-Pencil Mood Charts in Bipolar Disorder. J Dual Diagn (2012) 1.07
Age-appropriate cognition and subtle dopamine-independent motor deficits in aged tau knockout mice. Neurobiol Aging (2013) 1.06
Tau reduction prevents disease in a mouse model of Dravet syndrome. Ann Neurol (2014) 1.04
Surgical techniques for total sacrectomy and spinopelvic reconstruction. Neurosurg Focus (2003) 1.04
Quantifying biomarkers of cognitive dysfunction and neuronal network hyperexcitability in mouse models of Alzheimer's disease: depletion of calcium-dependent proteins and inhibitory hippocampal remodeling. Methods Mol Biol (2011) 1.02
PKCepsilon increases endothelin converting enzyme activity and reduces amyloid plaque pathology in transgenic mice. Proc Natl Acad Sci U S A (2006) 1.02
Altered navigational strategy use and visuospatial deficits in hAPP transgenic mice. Neurobiol Aging (2006) 1.00
Minimally invasive spinal surgery: a historical perspective. Neurosurg Focus (2004) 0.99